InsiderTrades.com logo
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
From Autonomix   |   Ad
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Invest in Autonomix today.

RNXT Insider Trading

Insider Ownership Percentage: 9.00%
Insider Buying (Last 12 Months): $1,155.00
Insider Selling (Last 12 Months): $0.00

RenovoRx Insider Trading History Chart

This chart shows the insider buying and selling history at RenovoRx by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

RenovoRx Share Price & Price History

Current Price: $0.62
Price Change: +0.30 (1.20%)
As of 12/8/2023 01:00 AM ET

This chart shows the closing price history over time for RNXT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
From Autonomix   |   Ad
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Invest in Autonomix today.

RenovoRx Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/3/2023Angela NelmsCOOBuy1,100$1.05$1,155.001,100View SEC Filing Icon  
6/7/2022Ramtin AgahInsiderBuy5,182$1.93$10,001.266,477View SEC Filing Icon  
5/19/2022Shaun BagaiCEOBuy5,500$2.05$11,275.00251,557View SEC Filing Icon  
See Full Table
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
From Autonomix   |   Ad
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Invest in Autonomix today.

SEC Filings (Institutional Ownership Changes) for RenovoRx (NASDAQ:RNXT)

2.29% of RenovoRx stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at RNXT by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

RenovoRx Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/8/2023Charles Schwab Investment Management Inc.49,232$62K0.0%N/A0.461%Search for SEC Filing on Google Icon
7/10/2023Level Four Advisory Services LLC15,000$34K0.0%+50.0%0.148%Search for SEC Filing on Google Icon
6/5/2023Level Four Advisory Services LLC10,000$35K0.0%N/A0.099%Search for SEC Filing on Google Icon
5/16/2023Geode Capital Management LLC42,100$0.15M0.0%+16.6%0.463%Search for SEC Filing on Google Icon
5/16/2023Armistice Capital LLC982,921$3.43M0.0%N/A10.801%Search for SEC Filing on Google Icon
1/19/2023Affinity Capital Advisors LLC15,259$36K0.0%+35.6%0.168%Search for SEC Filing on Google Icon
11/15/2022Colony Group LLC15,741$32K0.0%N/A0.174%Search for SEC Filing on Google Icon
11/10/2022Cohen Lawrence B54,121$0.16M0.1%-44.3%0.597%Search for SEC Filing on Google Icon
8/11/2022Cohen Lawrence B97,165$0.19M0.1%+79.5%1.072%Search for SEC Filing on Google Icon
8/2/2022Bank of The West975,000$1.93M0.2%N/A10.750%Search for SEC Filing on Google Icon
6/7/2022Bank of America Corp DE14,802$44K0.0%N/A0.163%Search for SEC Filing on Google Icon
5/13/2022Vanguard Group Inc.10,815$32K0.0%N/A0.120%Search for SEC Filing on Google Icon
5/13/2022Cohen Lawrence B54,121$0.16M0.1%N/A0.599%Search for SEC Filing on Google Icon
2/3/2022Cambridge Investment Research Advisors Inc.14,400$70K0.0%-64.7%0.162%Search for SEC Filing on Google Icon
11/16/2021Schonfeld Strategic Advisors LLC20,569$0.13M0.0%N/A0.245%Search for SEC Filing on Google Icon
11/16/2021Two Sigma Securities LLC17,944$0.11M0.0%N/A0.214%Search for SEC Filing on Google Icon
11/12/2021Board of Trustees of The Leland Stanford Junior University60,863$0.37M0.0%N/A0.726%Search for SEC Filing on Google Icon
11/2/2021Cambridge Investment Research Advisors Inc.40,850$0.25M0.0%N/A0.487%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
RenovoRx logo
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. The company was founded in 2009 and is headquartered in Los Altos, California.
Read More on RenovoRx

Today's Range

Now: $0.62
Low: $0.58
High: $0.62

50 Day Range

MA: $0.94
Low: $0.60
High: $1.22

52 Week Range

Now: $0.62
Low: $0.53
High: $5.75

Volume

50,053 shs

Average Volume

28,449 shs

Market Capitalization

$6.63 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of RenovoRx?

RenovoRx's top insider shareholders include:
  1. Shaun Bagai (CEO)
  2. Ramtin Agah (Insider)
  3. Angela Nelms (COO)
Learn More about top insider investors at RenovoRx.

Who are the major institutional investors of RenovoRx?

RenovoRx's top institutional investors include:
  1. Charles Schwab Investment Management Inc. — 0.46%
Learn More about top institutional investors of RenovoRx stock.

Which major investors are buying RenovoRx stock?

In the last quarter, RNXT stock was bought by institutional investors including:
  1. Charles Schwab Investment Management Inc.
During the last year, these company insiders have bought RenovoRx stock:
  1. Shaun Bagai (CEO)
  2. Ramtin Agah (Insider)
  3. Angela Nelms (COO)
Learn More investors buying RenovoRx stock.
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
From Autonomix   |   Ad
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Invest in Autonomix today.